RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on Hard-to-Treat brain cancer
Disease control Recruiting nowThis early-stage study is testing a new treatment for people with a rare and aggressive type of brain lymphoma that has returned or not responded to standard therapies. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer c…
Matched conditions: RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE1 • Sponsor: Beijing Boren Hospital • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New pill takes on hard-to-treat brain cancer in global trial
Disease control Recruiting nowThis study tests a new drug called tirabrutinib against a standard combination therapy (rituximab and temozolomide) in people whose primary central nervous system lymphoma has returned or not responded to prior treatment. About 132 adults with confirmed B-cell PCNSL will be rando…
Matched conditions: RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
Phase: PHASE3 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 19, 2026 11:47 UTC